Bl-8040.Scm.301- A Phase III, Randomized, Double-Blinded Placebo-Controlled, Multi-Centre Study Evaluating The Safety, Tolerability And Efficacy Of Combination Treatment Of Bl- 8040 And G-Csf As Compared To Placebo And G-Csf For The Mobilization Of Hemato
Posted Date: Oct 1, 2019
- Investigator: Tahir Latif
- Specialties: Cancer, Oncology
- Type of Study: Drug
The goal of this study is To demonstrate the superiority of one dose of BL-8040 + G-CSF over placebo + G-CSF to mobilize =6.0 x 106 CD34+ cells/kg in up to 2 apheresis sessions in preparation for autologous hematopoietic cell transplantation (auto-HCT) in MM subjects.
Criteria:
To Be Eligible: Between 18-78 Years Of Age, Diagnosed With Multiple Myeloma, Nonpregnant/Nonbreastfeeding, No Other Active Infection Or Metastases
Keywords:
Multiple Mylenoma, Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com